09:55 AM EST - Correvio Pharma Corp. : Announced that Brinavess® (vernakalant hydrochloride, IV), its antiarrhythmic drug for the rapid conversion of recent onset atrial fibrillation (AF), was selected by the China Food and Drug Administration's (CFDA) Center for Drug Evaluation (CDE) as potentially eligible for priority review. In the list published last week by the CDE, Brinavess was named one of 48 therapies assessed as "clinically urgently needed new drugs", and therefore eligible under the priority review pathway. Correvio Pharma Corp.
shares T.CORV are trading up $0.33 at $6.54.
